Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

NCT03061955 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT03061955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03061955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Lead sponsor
Wake Forest University Health Sciences
Phase
Observational
Overall status
Completed
Start date
October 1, 2016
Completion date
April 26, 2019
Enrollment
28 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, influenza virus vaccine adverse reaction (disorder), malignancy